Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

ClinicalTrials.gov ID: NCT00808418

Public ClinicalTrials.gov record NCT00808418. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of Weekly Elesclomol Sodium Plus Docetaxel and Concomitant Prednisone in Subjects With Metastatic Castration Refractory Prostate Cancer (m-CRPC)

Study identification

NCT ID
NCT00808418
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Enrollment
34 participants

Conditions and interventions

Interventions

  • Elesclomol Sodium Drug
  • Docetaxel Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2008
Primary completion
Apr 30, 2010
Completion
Apr 30, 2010
Last update posted
Feb 2, 2014

2008 – 2010

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Pacific Coast Hematology/Oncology Medical Group Fountain Valley California 92708
Mayo Clinic Rochester Maryland 55905
Mid Dakota Clinic Bismarck North Dakota 58501
University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development San Antonio Texas 78229
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00808418, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2014 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00808418 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →